Trial Profile
An Open-Label, Phase 1a/1b Study of Ramucirumab in Combination With Other Targeted Agents in Advanced Cancers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary) ; Merestinib (Primary) ; Ramucirumab (Primary)
- Indications Colorectal cancer; Mantle-cell lymphoma
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 02 Mar 2019 Status changed from active, no longer recruiting to completed.
- 22 Oct 2018 Planned End Date changed from 1 Jan 2019 to 1 May 2019.
- 22 Jun 2018 Planned primary completion date changed from 1 May 2018 to 1 Oct 2018.